Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus NAPRELAN.
CHILDREN'S MOTRIN vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category C
Category C
NSAID
NSAID